We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NeuroSense

News List

NeuroSense Reports Positive Results in ALS Study, Patent Allowance for PrimeC americanpharmaceuticalreview
March 08, 2021
NeuroSense Therapeutics has announced the successful completion of its first Phase IIa study. The study, NST002, aimed at establishing various safety endpoints for the company's first drug candidate PrimeC in 15 ALS patients, over a 12-month period.
NeuroSense Announces Continuation of Positive Trends in ALS Clinical Study americanpharmaceuticalreview
December 04, 2020
NeuroSense Therapeutics continues to report promising trends in their NST002 Phase IIa study, conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC).
NeuroSense Announces Encouraging Interim Results of Clinical Study in ALS americanpharmaceuticalreview
September 17, 2020
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced PrimeC was safe and well tolerated in the interim analysis of study NST002, a Phase IIa study conducted by ...